Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

It has been shown that the E/(e’×s’) index, which associates a marker of diastolic function (E/e’, early transmitral/diastolic mitral annulus velocity ratio) and a parameter that explores LV systolic performance (s’, systolic mitral annulus velocity), is a good predictor of outcome in acute anterior myocardial infarction. There are no studies that have investigated the prognostic value of E/(e’×s’) in a non-ST-segment elevated acute coronary syndrome (NSTE-ACS) population. Echocardiography was performed in 307 consecutive hospitalized patients with NSTE-ACS and succesful percutaneous coronary intervention, before discharge and six weeks after. The primary endpoint consisted of cardiac death or readmission due to re-infarction or heart failure. During the follow-up period (25.4 ± 3 months), cardiac events occurred in 106 patients (34.5%). Receiver operating characteristic (ROC) analysis identified E/(e’×s’) at discharge as the best independent predictor of composite outcome. The optimal cut-off value was 1.63 (74% sensitivity, 67% specificity). By multivariate Cox regression analysis, E/(e’×s’) was the only independent predictor of cardiac events. Kaplan–Meier analysis identified that patients with an initial E/(e’×s’) > 1.63 that worsened after six weeks presented the worst prognosis regarding composite outcome, readmission, and cardiac death (all p < 0.001). In conclusion, in NSTE-ACS, E/(e’×s’) is a powerful predictor of clinical outcome, particularly if it is accompanied by worsening after 6-weeks.

Details

Title
The Incremental Prognostic Value of E/(e’×s’) Ratio in Non-ST-Segment Elevated Acute Coronary Syndrome
Author
Ionac, Ioana 1   VIAFID ORCID Logo  ; Mihai-Andrei Lazăr 2 ; Daniel Miron Brie 3 ; Erimescu, Constantin 3 ; Vînă, Radu 4 ; Mornoş, Cristian 2   VIAFID ORCID Logo 

 Cardiology Department, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania; [email protected] (I.I.); [email protected] (C.M.) 
 Cardiology Department, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania; [email protected] (I.I.); [email protected] (C.M.); Cardiology Department, Institute of Cardiovascular Diseases, 300310 Timisoara, Romania; [email protected] (D.M.B.); [email protected] (C.E.) 
 Cardiology Department, Institute of Cardiovascular Diseases, 300310 Timisoara, Romania; [email protected] (D.M.B.); [email protected] (C.E.) 
 Viami Software, Viami Solution SRL, 011334 Bucharest, Romania; [email protected] 
First page
1337
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
20754418
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2565119860
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.